Type 2 Diabetes Mellitus (T2DM)

Metabolic Diseases
6
Pipeline Programs
8
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Peptide
150%
+ 5 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
Lifestyle interventionPhase 41 trial
Active Trials
NCT02670928Completed130Est. Apr 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
XigduoPhase 42 trials
Active Trials
NCT06327815Completed633Est. Jun 2025
NCT03038789Completed623Est. Aug 2019
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Maridebart CafraglutidePhase 2Peptide1 trial
Active Trials
NCT06660173Active Not Recruiting409Est. Nov 2026
Alnylam Pharmaceuticals
1 program
1
ALN-KHKPhase 1/21 trial
Active Trials
NCT05761301Terminated49Est. Apr 2025
M&
Merck & Co.RAHWAY, NJ
1 program
1
ErtugliflozinPhase 1Small Molecule1 trial
Active Trials
NCT01127308Completed6Est. Jul 2010
Celltrion
CelltrionKorea - Incheon
1 program
1
L03RD1Phase 11 trial
Active Trials
NCT07158346Completed49Est. Oct 2025
Abbott
AbbottABBOTT PARK, IL
1 program
Dietetic supportN/A1 trial
Active Trials
NCT06888687Recruiting156Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaXigduo
NovartisLifestyle intervention
AmgenMaridebart Cafraglutide
Alnylam PharmaceuticalsALN-KHK
CelltrionL03RD1
Merck & Co.Ertugliflozin
AbbottDietetic support
AstraZenecaXigduo

Clinical Trials (8)

Total enrollment: 2,055 patients across 8 trials

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Start: Mar 2024Est. completion: Jun 2025633 patients
Phase 4Completed
NCT02670928NovartisLifestyle intervention

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Start: Jul 2015Est. completion: Apr 2017130 patients
Phase 4Completed
NCT06660173AmgenMaridebart Cafraglutide

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Start: Nov 2024Est. completion: Nov 2026409 patients
Phase 2Active Not Recruiting

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Start: Mar 2023Est. completion: Apr 202549 patients
Phase 1/2Terminated

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

Start: Aug 2025Est. completion: Oct 202549 patients
Phase 1Completed

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

Start: Jun 2010Est. completion: Jul 20106 patients
Phase 1Completed
NCT06888687AbbottDietetic support

Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.

Start: May 2025Est. completion: Nov 2026156 patients
N/ARecruiting

XIGDUO Extended Release (XR) Post Marketing Surveillance

Start: Apr 2017Est. completion: Aug 2019623 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 2,055 patients
8 companies competing in this space